News
Chr. Hansen reports that a new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness.
In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.
Flu-like sickness can take its toll on workforce productivity, health care systems and families with young children, the company notes, and is estimated to have an annual burden on the US economy of $11.2 billion .
According to Chr. Hansen, data from numerous studies already shows a positive correlation between taking certain probiotics and reducing the number of incidents, duration and severity of flu-like sickness. This new study builds upon existing data, to assess the potential health economic impact of probiotics in the US primary care setting. The findings show the significant savings potential taking probiotics can have by reducing the number of sick days, visits to the doctor and prescriptions.
Flu-like sickness is a wide-ranging category including a fever of at least 100°F (37.8°C) and a cough or sore throat. On average over the last five years, there have been 33 million symptomatic cases in the US each year.
“Probiotics are already well established in the healthcare industry, and numerous studies have highlighted the therapeutic potential of specific probiotic strains in helping to maintain a healthy immune system and supporting the defense against harmful bacteria. In addition to the health benefits to an individual, this study demonstrates that taking probiotics also contributes to reducing costs to society and reducing the use of antibiotics. We believe that the impact of probiotics on healthcare will continue to grow in the years to come as we continue to unlock the potential of good bacteria,” said Andrew Scorey, senior vice president, Chr. Hansen Human Health.
Chr. Hansen points out that, according to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security and development today, and it is expected to exceed cancer as the main cause of death by 2050. It is estimated that more than one in three of the antibiotics prescribed to treat flu-like sickness in the US are redundant.
The new study reveals that in the US, some 2.2 million antibiotic courses could be avoided each year if the population takes probiotics.
“We already know that the overuse of antibiotics can cause bacteria to become resistant, meaning current treatments will no longer work. This study provides further evidence of how probiotics and ‘good bacteria’ can respond to some of the world’s biggest challenges,” said Scorey.
The results of the study are published in the journal Frontiers in Pharmacology and were authored and reviewed by independent industry and academic experts. Chr. Hansen sponsored the development of a new simulation model used in the study. The publication title is: Probiotics reduce healthcare cost and societal impact of flu-like respiratory tract infections in the USA: An economic modeling study.
The underlying data used in the study came from two independent reviews: York Health Economics Consortium (YHEC) and Cochrane. The clinical trials in these reviews used 22 probiotic strains, including Chr. Hansen’s Lactobacillus rhamnosus and Bifidobacterium animalis.
“This study builds on independent clinical trials and translates the clinical findings into cost and impact on primary health care. The results present a very strong case for probiotics. At Chr. Hansen, we will continue to build on these findings looking closely into how specific strains can support this health area. As a result of this study, we now have a new simulation model that will provide us with new ways to work with data in future studies,” said Adam Baker, senior manager, Human Health Development at Chr. Hansen.
Chr. Hansen owns some of the world’s best documented probiotic strains. The large number of scientific publications and clinical studies on these strains indicate that they may have beneficial effects on the immune functions.
23 Dec 2025
From trade tariffs to heavy metals in protein, we look back at some of the industry’s highlights of 2025 and round up our most-read stories of the year.
Read more
19 Dec 2025
Non-profit organisation the Food Foundation has launched a campaign, “Bang in Some Beans”, designed to increase UK consumers’ legume consumption.
Read more
12 Dec 2025
Europe’s $40.7 billion supplements market is growing fast, fuelled by demand for products that support healthy ageing, mental wellbeing, and preventive health, say experts.
Read more
11 Dec 2025
Whole Foods Market has released its top 2026 trends, predicting that a fibre frenzy will take place next year as health-conscious consumers seek out nutritious, filling options.
Read more
9 Dec 2025
With the launch of Novak Djokovic’s sorghum-based brand, the grain’s popularity in the better-for-you snacking sphere is on the rise, thanks to its nutritional and sensory properties.
Read more
8 Dec 2025
Plant-based dairy is a maturing market that still faces significant hurdles around taste, functionality, nutrition, and price, but industry is innovating fast, according to experts speaking at Fi Europe.
Read more
3 Dec 2025
Food industry stakeholders celebrated as the winners of the Fi Europe Innovation Awards were announced at a ceremony in Paris.
Read more
28 Nov 2025
Entries for the Vitafoods Europe Innovation Awards 2026 are now open! Game-changing companies have until 27 February to submit their entry across eight categories for the chance to win big.
Read more
25 Nov 2025
Cinnamon may be a top functional ingredient, but it needs stronger protocols to ensure it meets EU food safety laws and quality standards, say researchers.
Read more
24 Nov 2025
OXO’s entry into bone broth has turned the spotlight on this small but high-performance category – and there is still scope for growth, especially in the area of GLP-1 support.
Read more